# Open Label Trial of Immunotherapy for Advanced Liver Cancer

> **NCT02256514** · PHASE2 · UNKNOWN · sponsor: **Immunitor LLC** · enrollment: 120 (estimated)

## Conditions studied

- HCC
- Liver Cirrhosis

## Interventions

- **BIOLOGICAL:** Daily oral dose of hepcortespenlisimut-L

## Key facts

- **NCT ID:** NCT02256514
- **Lead sponsor:** Immunitor LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2019-09
- **Final completion:** 2019-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2019-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256514, "Open Label Trial of Immunotherapy for Advanced Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02256514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*